Insider Selling: ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells $76,395.74 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Mark Schneyer sold 3,506 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $21.79, for a total value of $76,395.74. Following the completion of the sale, the executive vice president owned 66,145 shares of the company’s stock, valued at approximately $1,441,299.55. The trade was a 5.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD stock opened at $22.58 on Friday. The company has a market cap of $3.87 billion, a P/E ratio of 10.26, a PEG ratio of 22.40 and a beta of 0.86. The stock has a 50 day simple moving average of $22.06 and a two-hundred day simple moving average of $23.90. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $14.68 and a fifty-two week high of $28.35.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The business had revenue of $268.10 million during the quarter, compared to the consensus estimate of $280.25 million. ACADIA Pharmaceuticals had a return on equity of 10.23% and a net margin of 34.30%.The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.11 earnings per share. On average, research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.45 earnings per share for the current year.

ACADIA Pharmaceuticals News Roundup

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Management highlighted strong early uptake of DAYBUE (DAYBUE STIX now broadly available) and said DAYBUE generated roughly $101M in Q1—supporting near-term revenue momentum and commercial execution. Acadia Q1 release
• Positive Sentiment: Company reaffirmed its full?year 2026 financial guidance (revenue range reiterated), which reduced downside uncertainty despite the quarter’s miss on street EPS and revenue. Guidance reaffirmation
• Neutral Sentiment: Full earnings presentation and the call transcript are available for investors wanting detail on commercial uptake, margin dynamics and pipeline updates—useful for modeling forward sales and margin trajectory. Earnings slide deck Earnings call transcript
• Negative Sentiment: Q1 EPS missed estimates: $0.02 vs. consensus $0.04, and revenue came in at $268.1M vs. ~$280M consensus. The EPS decline vs. prior year weakens near-term profitability optics and drove some analyst and media scrutiny. Zacks earnings summary
• Negative Sentiment: Insider selling disclosed (small volume): an officer sold ~1.3K shares recently—minor but noted by some investors. Insider trade filing

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC grew its holdings in ACADIA Pharmaceuticals by 67.5% during the fourth quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 386 shares in the last quarter. Cetera Investment Advisers grew its holdings in ACADIA Pharmaceuticals by 2.7% during the fourth quarter. Cetera Investment Advisers now owns 16,355 shares of the biopharmaceutical company’s stock worth $437,000 after buying an additional 436 shares in the last quarter. J.W. Cole Advisors Inc. boosted its position in ACADIA Pharmaceuticals by 2.5% in the fourth quarter. J.W. Cole Advisors Inc. now owns 20,632 shares of the biopharmaceutical company’s stock worth $551,000 after purchasing an additional 501 shares during the last quarter. Pallas Capital Advisors LLC boosted its position in ACADIA Pharmaceuticals by 4.0% in the fourth quarter. Pallas Capital Advisors LLC now owns 13,192 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 512 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in ACADIA Pharmaceuticals by 11.2% in the third quarter. PNC Financial Services Group Inc. now owns 5,323 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 534 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

Analysts Set New Price Targets

ACAD has been the subject of several recent research reports. Stifel Nicolaus decreased their price objective on ACADIA Pharmaceuticals from $25.00 to $24.00 and set a “hold” rating for the company in a report on Thursday, February 26th. Wolfe Research initiated coverage on ACADIA Pharmaceuticals in a report on Monday, February 23rd. They set an “outperform” rating and a $33.00 price objective for the company. TD Cowen boosted their price objective on ACADIA Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Royal Bank Of Canada decreased their price objective on ACADIA Pharmaceuticals from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Finally, Bank of America upgraded ACADIA Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $29.00 price objective for the company in a report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $31.21.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.